| RESEARCH PAPER |
|
| Year : 2020 | Volume
: 11
| Issue : 1 | Page : 13-18 |
|
|
Effect of nebivolol on microalbuminuria in hypertensive patients with or without type 2 diabetes mellitus
Padma Latha Merugu1, Thrilok Chander Bingi2
1 Department of Pharmacology, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, Telangana, India
2 Department of General Medicine, Gandhi Medical College/Hospital, Secunderabad, Telangana, India
Correspondence Address:
Thrilok Chander Bingi
Flat No: 605, Namita Everest, Bahadurguda, L.B. Nagar, Ranga Reddy, Hyderabad - 500 074, Telangana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jpp.JPP_95_19
|
|
|
Objective: To evaluate the effect of nebivolol on microalbuminuria (MA) in hypertensive patients with or without type 2 diabetes mellitus. Materials and Methods: This was an open-label, prospective study. Drug naive patients with stage I hypertension with or without type 2 DM with MA (urine albumin: creatinine ratio [UACR] between 30–300 mg/g) were enrolled in the study and were started on nebivolol 5 mg orally once daily. Efficacy parameters UACR, blood pressure (BP) were measured at baseline and 24 weeks. Paired t-test was used to analyze efficacy endpoints. P < 0.05 was considered to be statistically significant. Results: A total of 30 participants completed the study. Participants who received nebivolol showed a significant decrease in mean UACR, systolic BP, and diastolic BP at 24 weeks compared to baseline (P < 0.001). No participant discontinued the study because of adverse events. Conclusion: Nebivolol has a favorable effect on MA in addition to its antihypertensive effect in hypertensive patients. Further studies with large samples are required to characterize this effect of nebivolol on clinical outcomes.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
